Compare GLP-1 Medications: Ozempic, Wegovy, Mounjaro, Zepbound, and More
There are now more than eight GLP-1 medications on the US market, and picking between them can feel overwhelming. Some are approved for diabetes, some for weight loss, some for both; some cost $1,400 per month, others under $400; some are weekly injections, others are daily pills. This guide gives you a complete side-by-side comparison so you can understand your options and have an informed conversation with your physician.
- Tirzepatide (Mounjaro, Zepbound) produces the most weight loss, about 22.5% at top dose
- Semaglutide (Ozempic, Wegovy, Rybelsus) is the most prescribed and widely available
- Older GLP-1s (Saxenda, Trulicity) produce less weight loss but may suit specific patients
- A daily oral semaglutide pill exists (Rybelsus, plus Wegovy's new pill formulation)
- Best medication depends on your goals, budget, insurance, and side effect tolerance
The GLP-1 Landscape in 2026
The class has expanded rapidly since Ozempic's 2017 approval. Three core molecules now dominate: semaglutide, tirzepatide, and to a lesser extent liraglutide and dulaglutide. Each is sold under different brand names for different indications, which is why the lineup looks more confusing than it really is.
All GLP-1 medications work by mimicking gut hormones that regulate appetite and blood sugar. What differs is the exact mechanism (single-receptor vs dual-receptor), the half-life (daily vs weekly), the dose range, and which clinical indications they carry. Our GLP-1 medications explained article covers the class mechanics in detail, and our simple GLP-1 explainer is a good starting point if the terminology is new.
A notable 2025 development: Wegovy is now available as an oral pill, giving patients a needle-free option for weight management for the first time.
Master Comparison Table
The pattern is clear: tirzepatide leads on weight loss, semaglutide dominates in prescription volume, and older medications (Saxenda, Trulicity) are falling out of favor for weight management specifically. Our master Ozempic vs Wegovy vs Mounjaro comparison goes deeper on the top three.
Key Head-to-Head Matchups
Ozempic vs Wegovy: Same molecule (semaglutide), different approved indications and max doses. Ozempic tops out at 2.0 mg for diabetes; Wegovy reaches 2.4 mg for weight management. See our full Ozempic vs Wegovy breakdown for the clinical and cost differences.
Mounjaro vs Ozempic: Tirzepatide vs semaglutide, diabetes indication for both. Tirzepatide produces greater A1C reduction and significantly more weight loss. Our Mounjaro vs Ozempic comparison covers when each makes sense.
Wegovy vs Zepbound: Both are weight management products but use different molecules. Zepbound produces more weight loss on average and is also approved for obstructive sleep apnea, which can unlock Medicare coverage. Our Wegovy vs Zepbound guide covers the trade-offs.
Zepbound vs Mounjaro: Identical molecule, identical dosing. Differences are purely regulatory and financial. See our Zepbound vs Mounjaro comparison.
Trulicity vs Ozempic: Two weekly injectables for diabetes. Ozempic produces more weight loss and greater A1C reduction. Our Trulicity vs Ozempic comparison covers why most new prescriptions favor Ozempic.
Rybelsus vs Ozempic: Same molecule, different delivery. The Rybelsus vs Ozempic comparison and our broader pills vs shots breakdown explain why injectables still outperform pills on weight outcomes.
Saxenda vs Wegovy: Both are Novo Nordisk weight loss products, but Wegovy's weekly dosing and stronger results have largely replaced Saxenda's daily injection. Our Saxenda vs Wegovy comparison covers the remaining niches where Saxenda still makes sense.
Which Medication Is Right for You
The "best" GLP-1 depends on what you are optimizing for. A few practical decision rules cover most patients.
If your primary goal is maximum weight loss: Tirzepatide (Zepbound for weight management, Mounjaro if prescribed off-label for diabetes) produces the largest average results. LillyDirect vials have also made it meaningfully more affordable than it was two years ago.
If you have type 2 diabetes and want weight loss as a bonus: Either Ozempic (semaglutide) or Mounjaro (tirzepatide) work well. Tirzepatide produces more A1C reduction and weight loss; Ozempic has longer real-world safety data and broader insurance coverage.
If cost is the deciding factor: Compounded semaglutide through telehealth ($199 to $399/mo) is the most affordable path currently legal in the US. LillyDirect Zepbound vials at $349 to $499 are the next step up. Our affordable GLP-1 options guide covers the full landscape and our GLP-1 cost guide tracks current pricing.
If you want needle-free: Rybelsus (oral semaglutide for diabetes) and the new Wegovy oral pill (for weight management) are the only two legitimate options. Both produce less weight loss than their injectable counterparts.
If you have cardiovascular risk: Semaglutide has the strongest cardiovascular outcomes data from the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events. Our GLP-1 heart health overview covers the evidence.
If you need OSA coverage: Zepbound is the only GLP-1 FDA-approved for obstructive sleep apnea in adults with obesity, which can unlock Medicare and commercial insurance coverage that otherwise would not apply.
New and Upcoming Medications
The pipeline is active. Novo Nordisk is developing next-generation semaglutide formulations, including higher-dose Wegovy and extended-release variants. Eli Lilly has retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon) in late-stage trials, with early data suggesting weight loss potentially exceeding 24%. Several amylin co-agonists and oral tirzepatide candidates are also in development. Most of these are one to three years from market. Our latest GLP-1 research findings covers the pipeline in more detail.
Frequently Asked Questions
Which GLP-1 produces the most weight loss?
Tirzepatide (Mounjaro, Zepbound) produces the most weight loss, averaging 22.5% of body weight at the 15 mg dose in SURMOUNT-1. Semaglutide averages about 15% at the 2.4 mg dose in STEP 1.
Is Ozempic the same as Wegovy?
Both contain semaglutide and are made by Novo Nordisk, but Ozempic is approved for type 2 diabetes and maxes out at 2.0 mg weekly, while Wegovy is approved for weight management and goes up to 2.4 mg.
Can I switch from one GLP-1 to another?
Yes. Switching between GLP-1s is common when a medication stops producing results, causes tolerance issues, or becomes unaffordable. Your physician will typically restart you at a low dose on the new medication regardless of what dose you were on previously.
Which GLP-1 has the best insurance coverage?
Ozempic and Mounjaro (both diabetes indications) generally have broader commercial insurance coverage than their weight management counterparts. Zepbound's 2024 OSA approval has expanded Medicare coverage for many patients.
Are there GLP-1 pills that work as well as injections?
Not yet. Rybelsus (daily oral semaglutide) and the new Wegovy oral pill both produce meaningfully less weight loss than their injectable counterparts, largely due to absorption limitations. Oral tirzepatide candidates in development may narrow the gap.
Disclaimer
This content is for informational purposes and does not replace professional medical advice. Consult your physician before starting any medication.